Send to:

Choose Destination
See comment in PubMed Commons below
Hum Vaccin Immunother. 2014;10(6):1499-504. doi: 10.4161/hv.27985. Epub 2014 Mar 14.

A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Author information

  • 1Enteric Diseases Department; Naval Medical Research Center; Silver Spring, MD USA.


Campylobacter jejuni is a major cause of diarrheal disease and results in high levels of morbidity and economic loss in both industrialized and developing regions of the world. To date, prior vaccine approaches have failed to confer protection against this enteric pathogen. Key challenges to the development of a practical Campylobacter vaccine for human use include a lack of understanding of Campylobacter pathogenesis and well-defined immune correlates of protection. With the discovery that C. jejuni expresses a capsule polysaccharide associated with virulence, a conjugate vaccine approach is currently being evaluated. Conjugate vaccines have been successfully developed and implemented against other invasive mucosal pathogens including Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae. Furthermore, Shigella-based conjugate vaccines based on lipopolysaccharide have shown promising results in field trials. A prototype C. jejuni conjugate vaccine is currently entering human testing.


Campylobacter; GBS; capsular polysaccharide; conjugate vaccines; diarrheal disease

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk